Financial ChallengesDespite efforts, the company will not be cash flow positive until 2027, indicating ongoing financial challenges.
Quarterly PerformanceA slight miss in the quarter limits visibility as Part D drug costs and an MSSP true-up came in worse than anticipated.
Revenue DeclineIn 2025, the company expects a 2% decline in total revenue as MA enrollment declines and underperforming contracts are left.